These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 30070317

  • 1. LncRNA HOTAIRM1 inhibits the progression of hepatocellular carcinoma by inhibiting the Wnt signaling pathway.
    Zhang Y, Mi L, Xuan Y, Gao C, Wang YH, Ming HX, Liu J.
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4861-4868. PubMed ID: 30070317
    [Abstract] [Full Text] [Related]

  • 2. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
    Li L, Han T, Liu K, Lei CG, Wang ZC, Shi GJ.
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
    [Abstract] [Full Text] [Related]

  • 3. FBXO17 promotes malignant progression of hepatocellular carcinoma by activating wnt/β-catenin pathway.
    Liu FH, Cui YP, He YK, Shu RH.
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8265-8273. PubMed ID: 31646557
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.
    Sun SJ, Wang N, Sun ZW, Chen J, Cui HW.
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4869-4878. PubMed ID: 30070322
    [Abstract] [Full Text] [Related]

  • 7. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
    Li H, Yuan R, Wang H, Li C, Wei J.
    J BUON; 2020 Aug; 25(2):972-980. PubMed ID: 32521894
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Investigating function of long noncoding RNA of HOTAIRM1 in progression of SKOV3 ovarian cancer cells.
    Ye L, Meng X, Xiang R, Li W, Wang J.
    Drug Dev Res; 2021 Dec; 82(8):1162-1168. PubMed ID: 33939846
    [Abstract] [Full Text] [Related]

  • 10. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
    Ma CX, Gao WC, Tian L.
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
    [Abstract] [Full Text] [Related]

  • 11. LncRNA 00152 promotes the development of hepatocellular carcinoma by activating JAK2/STAT3 pathway.
    Li SJ, Sui MH, Sun ZX, Zhang WW.
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1038-1046. PubMed ID: 30779070
    [Abstract] [Full Text] [Related]

  • 12. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a.
    Wu S, Chen S, Lin N, Yang J.
    J Cell Mol Med; 2020 Mar; 24(5):3108-3116. PubMed ID: 31970876
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long non-coding RNA F11-AS1 inhibits HBV-related hepatocellular carcinoma progression by regulating NR1I3 via binding to microRNA-211-5p.
    Deng Y, Wei Z, Huang M, Xu G, Wei W, Peng B, Nong S, Qin H.
    J Cell Mol Med; 2020 Jan; 24(2):1848-1865. PubMed ID: 31880390
    [Abstract] [Full Text] [Related]

  • 15. The role of lncRNA ANRIL in the progression of hepatocellular carcinoma.
    Han W, Wang Q, Zheng L, Hong H, Yan B, Ma Y, Li X, Zhou D.
    J Pharm Pharmacol; 2021 Jul 07; 73(8):1033-1038. PubMed ID: 34111289
    [Abstract] [Full Text] [Related]

  • 16. LncRNA RUNX1-IT1 inhibits proliferation and promotes apoptosis of hepatocellular carcinoma by regulating MAPK pathways.
    Yan PH, Wang L, Chen H, Yu FQ, Guo L, Liu Y, Zhang WJ, Bai YL.
    Eur Rev Med Pharmacol Sci; 2019 Oct 07; 23(19):8287-8294. PubMed ID: 31646558
    [Abstract] [Full Text] [Related]

  • 17. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
    Wang MR, Fang D, Di MP, Guan JL, Wang G, Liu L, Sheng JQ, Tian DA, Li PY.
    Int J Med Sci; 2020 Oct 07; 17(9):1224-1234. PubMed ID: 32547318
    [Abstract] [Full Text] [Related]

  • 18. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
    Lei T, Zhu X, Zhu K, Jia F, Li S.
    Cancer Biol Ther; 2019 Oct 07; 20(7):1007-1016. PubMed ID: 30929558
    [Abstract] [Full Text] [Related]

  • 19. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
    Bao J, Chen X, Hou Y, Kang G, Li Q, Xu Y.
    Biomed Pharmacother; 2018 Nov 07; 107():824-833. PubMed ID: 30142544
    [Abstract] [Full Text] [Related]

  • 20. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG, Pan YW, Feng J, Zeng CT, Zhao XQ, Liang B, Zhang WW.
    Eur Rev Med Pharmacol Sci; 2019 Mar 07; 23(5):2003-2012. PubMed ID: 30915743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.